Partnering in Central Nervous System Diseases
We are looking for new early-science collaborations. Join our expanding community of innovation partners in central nervous system diseases.
Search
Tackling supply chain challenges for a country at war
We are there for our patients – even in crisis regions. A supply chain success story with our Ukrainian colleague Tetiana Nagirna from Kyiv.
Patient Safety & Pharmacovigilance at Boehringer Ingelheim
Patients inspire us in our mission to lead the science that creates breakthrough therapies, so that our medicines transform patients’ lives.
Engineering & Facilities
Engineering & Facilities
Manufacturing & Supply Chain
Manufacturing & Supply Chain
clinical-collaboration-with-Amgen
Collaboration to study Boehringer Ingelheim’s SOS1::pan-KRAS Inhibitor in combination with Amgen’s KRASG12C Inhibitor
BIVF funding more than doubled to 250 M€
Boehringer Ingelheim increases funding for its corporate venture fund, the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million
emperor-reduced-heart-failure-toplineresults
Positive, top-line results announced from the EMPEROR-Reduced Phase III trial in adults with chronic heart failure with reduced ejection fraction
commitments to sustainable development
On One Health Day, Boehringer Ingelheim shares an update on its strategic approach to sustainability for employees, partners and wider communities
Vaccine bluetongue virus serotype 3 sheep cattle
BULTAVO 3™ is a new vaccine that protects cattle and sheep against bluetongue virus serotype 3 (BTV-3). BULTAVO 3™ is the first BTV-3 vaccine that prevents clinical signs and mortality.
License to develop new fibro-inflammatory disease treatments
License to develop new fibro-inflammatory disease treatments
New production center for Veterinary Public Health
Boehringer Ingelheim invests more than €200 million to establish a strategic production center for Veterinary Public Health in Lyon, France.
Clinical-phase2-trials-NASH-and-obesity
Boehringer Ingelheim and Zealand Pharma announced Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults living with obesity or NASH.
InPedILD_trial_enrollment
First patient enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents
Boehringer Ingelheim Business Services Philippines Inc. | Careers
Boehringer Ingelheim Business Services Philippines Inc. | Careers
opening-solids-launch-fabrik
Boehringer Ingelheim today opened a tablet factory at Ingelheim in the presence of the State Premier of Rhineland-Palatinate, Malu Dreyer.
inauguration_biopharmaceutical_production_facility_vienna
The state-of-the-art biopharmaceutical production facility in Vienna is the single largest investment in the company's history.
emperor-preserved-chmp-positive-opinion
CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction
Sales consultant about working with purpose
Bok talks about how he found purpose in his career. After his father was diagnosed with cancer, he decided to work as an oncology sales consultant.
Phase II clinical trial weight loss results
Data shows nearly 19% weight loss in people with overweight or obesity in Phase II trial with survodutide (BI 456906)
Partnership with Precision Health Research, Singapore
Boehringer Ingelheim joins forces with Precision Health Research, Singapore with the aim of transforming healthcare and improving patient outcomes in Singapore and beyond.
Overcoming heartworm disease for homeless pets
Heartworm-free pets soar to new lives. Together with our Greater Good Charity partners, our colleagues helped bring shelter dogs to forever homes.
FIBRONEER™ Phase III program initiated
FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor
AI&Data Science Fellowship Tuebingen
AI&Data Science Fellowship Tuebingen
Ann-Kathrin Koller
Diverse, caring, collaborative - Ann-Kathrin Koller on Boehringer Ingelheim